Synergistic Hepatic Disease Treatment System

Publication ID: 24-11857577_0003_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic Hepatic Disease Treatment System,” Published Technical Disclosure No. 24-11857577_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857577_0003_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,577.

Summary of the Inventive Concept

A novel system integrating patented compositions for treating hepatic diseases and disorders with advanced technologies such as AI, IoT, blockchain, and new materials to provide personalized, real-time treatment and monitoring.

Background and Problem Solved

The original patent disclosed compositions and methods for treating hepatic diseases and disorders, but it had limitations in terms of personalization, real-time monitoring, and adaptability. The new inventive concept addresses these limitations by integrating the patented compositions with cutting-edge technologies to provide a more effective and efficient treatment system.

Detailed Description of the Inventive Concept

The new system comprises a pharmaceutical composition according to claim 1, a wearable device configured to monitor the patient's health metrics, and a machine learning algorithm that analyzes the health metrics and adjusts the pharmaceutical composition in real-time. Additionally, the system may include a blockchain-based platform for analyzing a patient's genetic profile and medical history, IoT-enabled devices for generating a customized treatment plan, and a nanoparticle-based delivery system that targets the liver. The system may also incorporate a non-invasive diagnostic device that uses AI-powered imaging to detect liver damage, and a predictive model of treatment outcomes using a blockchain-based platform.

Novelty and Inventive Step

The new claims introduce a synergistic combination of the patented compositions with advanced technologies, providing a novel and non-obvious solution for treating hepatic diseases and disorders. The integration of these technologies enables real-time monitoring, personalization, and adaptability, which are not possible with the original patent alone.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept may include different types of wearable devices, blockchain-based platforms, or IoT-enabled devices. The system may also be adapted for use in different medical settings, such as hospitals or clinics, or for use in conjunction with other treatment modalities.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of personalized medicine and precision health. The system may be marketed as a comprehensive solution for treating hepatic diseases and disorders, offering improved treatment outcomes and reduced healthcare costs.

Field of Art

Pharmaceutical biotechnology, specifically hepatic disease treatment technologies with a focus on immunomodulatory compositions and digital health integration

Person of Ordinary Skill (PHOSITA) Profile

A biomedical engineer or pharmaceutical researcher with expertise in immunology, drug delivery systems, medical device technologies, and machine learning applications in personalized medicine

Obviousness Rationale

A PHOSITA would recognize that integrating digital monitoring technologies with pharmaceutical compositions represents a predictable and incremental advancement in personalized medicine. The combination of TLR-activating bacterial lysates with AI-driven monitoring and treatment adaptation follows established trends in precision healthcare technologies. The disclosed system represents a logical extension of existing pharmaceutical and digital health paradigms, utilizing well-understood technologies to enhance treatment monitoring and personalization.

Obvious Combinations & Variations

Source Patent Element
Liquid formulation with bacterial lysate containing TLR ligands for hepatic disease treatment
PTD Variation
Adding nanoparticle-based targeted delivery system for enhanced pharmaceutical composition
Obviousness Reasoning
Nanoparticle drug delivery is a known technique for improving pharmaceutical targeting, and a PHOSITA would find it obvious to enhance the original composition's efficacy through targeted delivery mechanisms
Source Patent Element
Pharmaceutical composition for hepatitis treatment
PTD Variation
Incorporating wearable device and machine learning algorithm for real-time health metric monitoring and treatment adjustment
Obviousness Reasoning
Integration of IoT and AI technologies with medical treatments is a predictable advancement in personalized medicine, representing a design choice within the ordinary skill of the art
Source Patent Element
Bacterial lysate composition for immune modulation
PTD Variation
Blockchain-based platform for analyzing genetic profiles and generating personalized treatment plans
Obviousness Reasoning
Personalized medicine approaches using genetic analysis and digital platforms are well-established techniques for tailoring medical interventions, representing an obvious combination of known technologies
Source Patent Element
Pharmaceutical composition targeting hepatic diseases
PTD Variation
AI-powered non-invasive diagnostic imaging for liver damage detection
Obviousness Reasoning
Application of machine learning to medical imaging is a known technique, and a PHOSITA would find it obvious to integrate diagnostic technologies with existing treatment methodologies
35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. ยง 103, the variations disclosed herein would have been obvious to a person having ordinary skill in the art at the time of invention, as they represent predictable combinations of known pharmaceutical compositions (US 11857577) with established digital health technologies, demonstrating no inventive step beyond the ordinary capabilities of skilled practitioners in the field of hepatic disease treatment and personalized medicine.

Original Patent Information

Patent NumberUS 11,857,577
TitleCompositions and methods for the treatment of hepatic diseases and disorders
Assignee(s)Labyrinth Holdings, LLC